A detailed history of New York State Common Retirement Fund transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 36,678 shares of RLAY stock, worth $233,272. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,678
Previous 36,678 -0.0%
Holding current value
$233,272
Previous $404,000 24.75%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 01, 2024

BUY
$6.01 - $11.48 $6,773 - $12,937
1,127 Added 3.17%
36,678 $404,000
Q3 2023

Nov 07, 2023

BUY
$8.24 - $12.97 $2,949 - $4,643
358 Added 1.02%
35,551 $299,000
Q2 2023

Aug 07, 2023

SELL
$9.99 - $18.27 $207,022 - $378,609
-20,723 Reduced 37.06%
35,193 $442,000
Q1 2023

May 02, 2023

SELL
$15.0 - $22.76 $186,465 - $282,929
-12,431 Reduced 18.19%
55,916 $921,000
Q4 2022

Jan 30, 2023

SELL
$14.16 - $24.02 $269 - $456
-19 Reduced 0.03%
68,347 $1.02 Million
Q3 2022

Nov 08, 2022

BUY
$18.07 - $31.37 $89,862 - $156,003
4,973 Added 7.84%
68,366 $1.53 Million
Q2 2022

Aug 04, 2022

BUY
$13.31 - $34.88 $147,594 - $386,784
11,089 Added 21.2%
63,393 $1.06 Million
Q1 2022

May 05, 2022

BUY
$20.26 - $32.36 $174,479 - $278,684
8,612 Added 19.71%
52,304 $1.57 Million
Q4 2021

Feb 02, 2022

BUY
$26.0 - $37.03 $12,792 - $18,218
492 Added 1.14%
43,692 $1.34 Million
Q3 2021

Nov 02, 2021

SELL
$29.75 - $37.99 $219,941 - $280,860
-7,393 Reduced 14.61%
43,200 $1.36 Million
Q2 2021

Aug 02, 2021

BUY
$27.5 - $38.19 $365,557 - $507,659
13,293 Added 35.64%
50,593 $1.85 Million
Q1 2021

May 11, 2021

BUY
$32.52 - $61.53 $263,412 - $498,393
8,100 Added 27.74%
37,300 $1.29 Million
Q3 2020

Nov 05, 2020

BUY
$32.81 - $45.1 $958,052 - $1.32 Million
29,200 New
29,200 $1.24 Million

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $765M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.